- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01144325
Minimally Invasive Esophagectomy (MIE) in Prone Versus Left Decubitus Position
Minimally Invasive Esophagectomy in Prone or Left Decubitus Position: A Prospective Randomized Clinical Trial From A Single Institution
The purpose of this prospective randomized study is to compare clinical outcomes from two different patient position(prone vs left decubitus)with thoracoscopic esophageal mobilization in the procedure of Minimally Invasive Esophagectomy (MIE).
- Comparing morbidities from the two groups
- Comparing short-term quality of life from the two groups
- Comparing oncological results (3,5 year survival) from the two groups
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Thoracoscopic esophagectomy is routinely performed in two positions. The left decubitus position is the most commonly used position at most centers. However prone position is another alternative.
The left decubitus position is advocated for its the same position as the open procedure and easy to learn, as well as easy to emergent conversion to open thoracotomy .However, the disadvantage of this position is the need of lung retraction for better exposure and definitely one lung ventilation. They are regarded as potential causes leading lung injury.
Prone thoracoscopic esophageal mobilization has been advocated for its potential benefits of increased operative exposure, no lung retraction, avoid one lung ventilation, improved surgeon ergonomics. But it is difficult to make emergent conversion under this positon and not familiar with most thoracic or digestive surgeons. A longer learning curve may be needed.
A few publications have compared the two position with thoracoscopic mobilization of the esophagus in retrospective study of a small cohort. Until now, no prospective randomized study has been carried out in this field.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200032
- Recruiting
- Zhong Shan Hospital, Fu Dan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical stage I/II esophageal cancer
- normal blood test of basic metabolism panel
- pulmonary function: FEV1 > 1.2L, FEV1% > 50%, DLCO > 50%
- heart function: NY grade I and grade II
- sign informed consent
Exclusion Criteria:
- Patients who received neoadjuvant therapy
- Mental disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Perioperative morbidity and mortality from the two groups
Time Frame: 1 -5 years after surgery
|
1 -5 years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
short-term quality of life(postoperative 6 months and 1 year) between the two groups
Time Frame: 1 year
|
1 year
|
|
3-and 5-year survival rate between the two groups
Time Frame: 1 - 5 years after surgery
|
1 - 5 years after surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ZSchest2010001
- MIEFUDANU2010001 (Other Identifier: Zhong Shan Hospital, Fu Dan University)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.